Undermining Value-Based Purchasing — Lessons from the Pharmaceutical Industry
Although it's not yet clear how health care providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid. In 2015, the U.S. Department of Health and Human Services announced a...
Uloženo v:
| Vydáno v: | The New England journal of medicine Ročník 375; číslo 21; s. 2013 - 2015 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Massachusetts Medical Society
24.11.2016
|
| Témata: | |
| ISSN: | 0028-4793, 1533-4406 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | Although it's not yet clear how health care providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid.
In 2015, the U.S. Department of Health and Human Services announced a goal of linking at least 50% of Medicare spending to value-based payment models such as accountable care organizations.
1
Health care providers are now scrambling to reorganize in a way that delivers value while preserving or enhancing commercial success. Although it’s not yet clear how providers will respond to value-based payment models, an examination of pharmaceutical industry practices can provide insights into problems that may arise — and practices to avoid.
Value-based plan design — a term that describes payers’ efforts to align consumer cost sharing with the value . . . |
|---|---|
| Bibliografie: | SourceType-Scholarly Journals-1 ObjectType-Commentary-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 0028-4793 1533-4406 |
| DOI: | 10.1056/NEJMp1607378 |